PCV2 An Analysis of the Economics of Hypertension  by West, DS & Corey, R
Abstracts
ECONOMIC AND OUTCOMES ISSUES IN
CARDIOVASCULAR DISEASE
PCY.
FACTORS INFLUENCING THE DECISION TO
TREAT SERUM LIPID DISORDERS BY DRUG
THERAPY IN THE PRIMARY CARE VENUE
Yuan Y, Silbert G, Doyle J, Copeland K
IMS America, Plymouth Meeting, PA USA
OBJECTIVE: To identify risk factors associated with the
decision to prescribe drug therapy within the first year of
diagnosis.
METHODS: Selected all patients diagnosed with hyper-
cholesterolemia/hyperlipidemia before October 1996 (so
that patients are followed for one year) and who had se-
rum lipid levels recorded prior to initial diagnosis from a
electronic medical records database. Logistic regression
analysis was the tool employed to evaluate the following
factors: age, gender, serum lipid levels and comorbidities
(hypertension, diabetes, coronary heart disease, obesity,
and tobacco use disorder as a surrogate for smoking),
and various combinations.
RESULTS: The total number of patients included in the
analysis was 3,177, with 34.6% prescribed therapy
within one year of diagnosis. For initial therapy, 79.6%
were treated with statins, 6.0% with sequestrants, 10.1 %
with gemfibrozil, and 4.3% with niacin. Among those
treated, 92.9% remained on therapies within the class of
their initial treatment. Age, diabetes, HDL < 35 mg/dL,
LDL ~ 190 mg/dL, CHD and LDL > 130 mg/dL, no
CHD and either fewer than two risk factors with LDL ~
190 or with two or more risk factors and LDL ~ 160
were positively associated with, and presence of tobacco
use disorder was negatively associated with the decision
to prescribe drug therapy within the first year (p = 0.05).
CONCLUSIONS: A range of factors influence prescrip-
tion of antilipemic therapy during the first year after di-
agnosis. This decision has implications for resources de-
voted to patient management during the first year.
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Given the economic burden of hypertension and its con-
sequences (i.e., $259 billion in the United States per year),
it is important to identify effective treatment strategies
that use limited medical resources. Thus, economic stud-
ies are continually being conducted in order to provide
clinicians with information on cost-effective management
of hypertension. The purpose of this analysis was to eval-
uate economic studies in hypertension management and
to recommend suggestions for future research.
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METHODS: An extensive review of the literature per-
taining to the economics of hypertension was completed.
Each study was then evaluated, and the methodologies
and results were compared. The studies were also com-
pared to the JNC-VI guidelines.
RESULTS: First, few long-term economic evaluations are
available to aid in determining the most efficient and ef-
fective strategies for managing hypertension in individual
patients or patient groups. Second, the economic analyses
of hypertension are difficult to compare since their meth-
odologies varied widely. In general, they focused on ini-
tial monotherapy, and many of the assumptions regard-
ing treatment were questionable. The studies did not
include all the variables the JNC-VI guidelines refer to
when making therapy decisions.
CONCLUSIONS: Additional economic evaluations that
use a consistent methodology and that include all vari-
ables shown to affect cost-effectiveness ratios, including
the ones considered in developing the JNC-VI guidelines,
are necessary. In addition, economic evaluations of com-
bination products and changes in initial therapy are neces-
sary since these affect the total cost of hypertension treat-
ment. Other considerations for future evaluations (e.g.,
compliance issues, quality of life issues) are reviewed.
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OBJECTIVE: To compare the rate of drug therapy initia-
tion, and the time to treatment for men and women diag-
nosed with lipid disorders.
METHODS: From an electronic medical records database
extracted from primary care doctors' systems, patients
newly diagnosed with hypercholesterolemia/hyperlipi-
demia from October 1, 1993 through September 30, 1996
were selected. Patients were followed through September
30, 1997 resulting in a follow-up time of one to four years.
Patients must have blood cholesterol readings recorded
prior to initial diagnosis. Kaplan-Meier estimation and
Cox regression were used for the analysis. Risk factors
considered include age, estrogen replacement therapy, se-
rum lipid levels, and comorbidities (hypertension, diabetes,
CHD, obesity, and tobacco abuse disorder).
RESULTS: A total of 2,692 patients was included in the
analysis, with 1,223 male and 1,469 female. Among these
patients, 33.4% of the males and 34.5% of the females (p
= 0.58) were prescribed drug therapy within a year of di-
agnosis. Time to treatment between males and females
was not significantly different (Log-rank test, p = 0.83).
Gender was not a significant predictor when controlling
for other risk factors (Cox regression, p = 0.91). For pa-
tients in the two highest risk groups according to Na-
tional Cholesterol Education Program (NCEP) guidelines,
